Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
[기재정정]금전대여결정
Regulatory Filings
2026-04-30 Korean
[기재정정]주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement concerning the setting and correction of the shareholder register closure period and record date for an extraordinary general meeting. It does not present financial results, management changes, dividend details, or capital transactions, nor is it a proxy statement or board composition update. It is a general regulatory disclosure that falls into the fallback category “Regulatory Filings (RNS).”
2026-04-24 Korean
[기재정정]주주총회소집결의 (임시주주총회)
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement of the convocation and scheduling (with corrections) of an extraordinary shareholders’ meeting. It is not the full meeting materials (AGM materials), proxy statement, vote results, or a financial report. Therefore it falls under the general Regulatory Filings category (RNS).
2026-04-24 Korean
투자판단관련주요경영사항 (경영지배인 사임)
Board/Management Information Classification · 1% confidence The document is a disclosure of a senior management change (“경영지배인 사임” – resignation of a managing executive), matching the definition for Board/Management Information. It is not a full report but an announcement of a management change. Therefore, it should be classified under code MANG.
2026-04-23 Korean
금전대여결정
Capital/Financing Update Classification · 1% confidence The document is a corporate announcement detailing a board resolution to extend a loan (금전대여결정) of KRW 14 billion to Primecore Co. It covers loan amount, interest rate, period, collateral, board resolution date, and related-party details. It is not an earnings release, management change, dividend notice, or share transaction. The content pertains to a financing activity (use of company funds to lend money), so it best fits the Capital/Financing Update category (CAP).
2026-04-21 Korean
기타시장안내 (상장폐지 관련 이의신청서 접수 및 개선기간 부여)
Delisting Announcement Classification · 1% confidence The document is a formal market notice (“기타시장안내”) regarding delisting proceedings: it explains that a company’s audit opinion qualified on going concern grounds has triggered delisting rules, describes submission of an objection, and the granting of an improvement period under the KOSDAQ listing regulations. This is not an annual report or earnings release but a regulatory announcement about the delisting process. It matches the Delisting Announcement category.
2026-04-21 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.